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Abstract
Background: Molluscum contagiosum (MC) is a frequent and usually benign
cutaneous infection with molluscum contagiosum virus (MCV), affecting main-
ly children and young sexually active adults. With the emergence of HIV/AIDS,
a new patient group at risk has been identified with often extensive skin involve-
ment and recalcitrant disease.
Main observations: We report a case of a girl with connatal HIV-infection,
suffering from extensive, disseminated MC. Due to multi-resistance, an effec-
tive antiretroviral therapy could not be established for years, rendering an effec-
tive treatment of MC by established treatment options virtually impossible. An
off-label use of imiquimod showed a marked improvement of lesion counts in
this patient, whereas a complete clearance could only be achieved once effective
antiretroviral therapy was introduced.
Conclusions:We believe that imiquimod may represent a valuable treatment
option for molluscum contagiosum especially in the context of marked immu-
nosuppression, where sensitive areas like the face and neck are often involved
and scarring must be avoided. (J Dermatol Case Rep. 2011; 5(2): 19-23.)
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Introduction
Molluscum contagiosum (MC) are very common cutane-
ous warts caused by molluscum contagiosum virus (MCV),
a double-stranded DNA virus of the poxvirus family. The ty-
pical clinical presentation consists of small, umbilicated,
skin-coloured, pearly papules with predilection of the trunk,
axillae, antecubital and popliteal fossae and genital area. In-
cidence first peaks in pre-school children.1 A second inci-
dence peak occurs in young adults, where the condition is
generally considered a sexually transmitted infection. HIV-
positive patients were identified as a risk group in the 1980’s
with incidence rates of up to 18% in infected individuals.2-4
An inverse correlation between the number of molluscum
lesions and CD4-cell-counts could be demonstrated, iden-
tifying MC as a marker for pronounced immune dysfunc-
tion in this patient group.3 Immunosuppressed patients often
show extensive disease with frequent involvement of face,
neck and genital area and atypical clinical presentation.5 In
advanced stages of immunosuppression, giant or verrucous
forms of MC may occur.6,7
In immunocompetent individuals, lesions usually clear
spontaneously within several months or years, whereas in
immunosuppressed patients, the disease tends to take a
more chronic course and often is unresponsive to various
treatments. Many different therapeutic options for MC have
been described, which can be divided into destructive, cy-
totoxic, antiviral and immune-modifying modalities.8,9 Late-
ly, particular interest has been paid to the topical immune
modulator imiquimod, a member of the imidazoquinoline
family. Imiquimod stimulates TLR7 and TLR8, inducing an
antiviral local immune response.10 Several trials showed
good clinical response of molluscum lesions to treatment
with imiquimod, although mainly in immunocompetent pa-
tients.9,11-15 Limited data on the use of imiquimod in adult
HIV-positive individuals is available,16-19 mainly on the ba-
sis of case reports or small case series.
Here, we report a case of extensive MC in a girl with con-
natal HIV-infection who showed improvement of her lesions
with topical imiquimod. Complete clearance of all lesions
could only be achieved once highly active antiretroviral the-
rapy was established.
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significant scarring as a result. On continued and effective
HAART, the patient has remained free of mollusca contagio-
sa since 20 months.
Discussion
MC usually resolve spontaneously after several months
to years in immunocompetent individuals. Lesions may spre-
ad, however, until they eventually resolve. Outcomes are
less favorable in immunosuppressed individuals.4 Therefo-
re, treatment is generally advised to prevent sexual trans-
mission, autoinoculation and potential scarring and is often
requested by the affected patients.21
MCV has different mechanisms of evading host immune
responses. It produces chemokines which result in inhibi-
tion of monocyte function and leukocyte migration into the
site of infection.8 Correspondingly, a reduced number of
Langerhans cells, the main antigen presenting cells of the
epidermis, could be demonstrated in areas of molluscum
lesions both in immunocompetent and immunodeficient in-
dividuals.22 Further, MCV encodes for a major histocompa-
tibility complex (MHC) I-like heavy chain homolog that lacks
important parts for peptide binding and presentation and
might therefore interfere with presentation of MCV antigens
on the surface of infected cells.23 Additionally, MCV produ-
ces a caspase 8 inhibitor, resulting in decreased apoptosis
secondary to death-receptor signals like FAS and thus pro-
longed survival of infected cells.24
Imiquimod, a member of the imidazoquinoline family, has
potent antiviral and antiproliferative properties. It induces
the production of a wide range of proinflammatory and an-
tiviral cytokines like interferon-α, IL-12, TNF-α and interfe-
ron-γ10,25 followed by the activation of innate and Th1-weigh-
ted acquired immunity. An activation of Langerhans cells
with upregulated antigen presentation and increased migra-
tion to the draining lymph nodes could be shown.26 More-
over, imiquimod seems to directly induce apoptosis inde-
pendent of death-receptors via the mitochondrial pathway.27
These observations provide a good rationale for the use
of imiquimod in viral infection. Indeed, a strong antiviral
efficacy has been demonstrated in numerous trials on con-
dylomata acuminata (HPV),28 but there is increasing eviden-
ce from open as well as double-blind, controlled trials for
good clinical results in infections with MCV,9,11-15 also in
comparison to other established treatment options.9,13 Fur-
thermore, imiquimod led to successful outcome of MCV
in immunocompromised patients, although primarily repor-
ted as single cases.16-19,29 Compared with many destruc-
tive therapies, imiquimod is atraumatic, usually non-scar-
ring and therefore well suited for use in children. A recent
safety study on imiquimod showed good tolerability in this
patient group.30
We could observe a good clinical response to treatment
with imiquimod in our patient as compared to the opposing
leg treated only with salicylic acid 5% in petrolatum. Complete
clearance, however, was not achieved. Occlusive treatment
resulted in increased efficacy probably due to the improved
penetration of the drug. Complete cure was reached after
establishment of a highly active antiretroviral therapy and
Case report
An 11-year-old girl with connatal HIV-infection presented
to our out-patient clinic for immunosuppressed patients with
extensive, confluent, umbilicated papules on all extremities
and the trunk. Lesions had first appeared several months be-
fore presentation. A clinical diagnosis of extensive giant MC
was confirmed by histology (Fig. 1). At the time, the patient
was on antiretroviral therapy, but due to multi-resistance,
the viral-load was high at 183927 copies/mL, and CD4-cell
counts were at 160/μL, consistent with a marked suppres-
sion of cellular immunity. Atopy was present based on per-
sonal history and skin tests, which constitutes a risk factor
for extensive MC disease.20
Surgical removal of several lesions had been performed
before, resulting in significant scarring. The patient at the
time declined further cryotherapy or curettage. Because of
the widespread disease, we prescribed off-label imiquimod
5%-cream on the right leg. The left side was treated with sa-
licylic acid 5% in petrolatum only. Application of imiquimod
three times weekly showed no significant improvement after
3 months. We therefore stepped up the treatment to 5 weekly
applications under occlusion on the right leg. Eight weeks
with 5 applications weekly under occlusion showed a re-
markable improvement of the treated area (Fig. 2). Treat-
ment was therefore continued. Apart from mild erythema,
there were no relevant side effects observed or reported by
the patient. After 7 months of treatment, an approximately
50% improvement compared to the untreated regions could
be documented, while irritation with progressive extent of
the lesions was seen in the area treated with salicylic acid
5% in petrolatum (Fig. 2).
With the emergence of new anti-retroviral agents, high-
ly active anti-retroviral therapy (HAART) could be establi-
shed 4 years later. With CD4-cell counts returning to nor-
mal levels, clearance of almost all remaining mollusca was
achieved. Remaining lesions were removed surgically with
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Figure 1
Histology of MC in our patient showed lobulated, endophytic
hyperplasia of the epidermis and typical intracytoplasmic viral
inclusions.
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Figure 2
Clinical course of MC with (a) imiquimod, (b) salicylic acid 5% in petrolatum over time. Panel (c) shows CD4 count and HIV viral
copy number.
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surgical treatment of the remaining lesions, which resulted
in significant scarring. Healing of the lesions under HAART
has been described and is somewhat intuitive,31,32 although
a risk of a deterioration in the context of the immune recon-
stitution inflammatory syndrome has been reported.33
Conclusion
Reconstitution of normal immunologic function where
possible remains the mainstay of therapy for MC in immu-
nocompromised patients. Nevertheless, we think that imi-
quimod seems a valuable therapeutic option in immunosup-
pressed patients with recalcitrant MC infection of the skin,
where extensive disease frequently affects sensitive areas like
the face and neck and therefore scarring must be avoided.
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